Compare TIL & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIL | MRCC |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 133.2M |
| IPO Year | 2021 | 2012 |
| Metric | TIL | MRCC |
|---|---|---|
| Price | $6.66 | $6.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $100.67 | $8.00 |
| AVG Volume (30 Days) | 59.8K | ★ 139.6K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 11.06% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $43,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.17 | $5.86 |
| 52 Week High | $42.79 | $8.85 |
| Indicator | TIL | MRCC |
|---|---|---|
| Relative Strength Index (RSI) | 27.03 | 47.55 |
| Support Level | $10.17 | $5.99 |
| Resistance Level | $12.91 | $6.80 |
| Average True Range (ATR) | 0.74 | 0.21 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 13.40 | 58.21 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.